drugset / Trial / NCT00062387

Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT00062387

Phase 2 Terminated 46 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase II trial to study the effectiveness of perifosine in treating patients who have recurrent or metastatic head and neck cancer. Drugs used in chemotherapy such as perifosine use different ways to stop tumor cells from dividing so they stop growing or die.

Timeline

Start
2003-05
Primary completion
2007-01
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Perifosine Small molecule 100 mg Oral

Indications